AGI AGI

 

TIDMAGI 
 
RNS Number : 1823B 
AGI Therapeutics plc 
22 October 2009 
 

AGI Therapeutics plc 
 
 
Changes to Executive Team 
 
 
 
 
Dublin, Ireland, 22 October 2009 - AGI Therapeutics plc ("AGI" or the "Company") 
(AIM, IEX: AGI), a speciality pharmaceutical development company, announces 
today that Dr David Young, President of US Operations, and Dr Sian Bigora, Vice 
President, Clinical Research and Regulatory Affairs, are to leave the Company in 
the next few weeks. Dr Young will remain as a director of the Board of AGI 
Therapeutics, plc. 
 
 
 
 
Dr John Devane, CEO of AGI Therapeutics, commented: "We want to thank both David 
and Sian for their contribution to all aspects of our business and wish them 
every success in the future. We are particularly pleased that David will remain 
on our Board which will ensure we continue to receive his counsel on our US 
regulatory strategy for products being developed as part of our new business 
plan. We continue to make good progress on developing the operational plans and 
intellectual property positions that will support those projects which will be 
the focus of our development efforts over the coming years." 
 
 
End 
 
 
 
 
Contact Information: 
 
 
+------------------------------------------+------------------------------------+ 
| AGI Therapeutics plc.                    | Tel: +353 1 449 3254               | 
+------------------------------------------+------------------------------------+ 
| David Kelly, Chief Financial Officer     |                                    | 
+------------------------------------------+------------------------------------+ 
|                                          |                                    | 
+------------------------------------------+------------------------------------+ 
| Financial Dynamics - UK                  | Tel: +44 (0) 20 7269 7182          | 
+------------------------------------------+------------------------------------+ 
| Jonathan Birt/John Dineen                |                                    | 
+------------------------------------------+------------------------------------+ 
|                                          |                                    | 
+------------------------------------------+------------------------------------+ 
| Financial Dynamics - Ireland             | Tel: +353 1 663 3607               | 
+------------------------------------------+------------------------------------+ 
| Niamh Lyons                              |                                    | 
+------------------------------------------+------------------------------------+ 
|                                          |                                    | 
+------------------------------------------+------------------------------------+ 
| Piper Jaffray Limited                    | Tel: +44 (0) 20 3142 8700          | 
| Neil Mackison                            |                                    | 
| Will Carnwath                            |                                    | 
+------------------------------------------+------------------------------------+ 
|                                          |                                    | 
+------------------------------------------+------------------------------------+ 
| Davy                                     | Tel: +353 1 614 8761               | 
| John Frain                               |                                    | 
+------------------------------------------+------------------------------------+ 
 
 
For further information please see www.agitherapeutics.com. 
 
 
 
 
Notes to Editors: 
 
 
 
 
About AGI Therapeutics plc 
 
 
AGI is a specialty pharmaceutical company which is focused on the development 
and commercialisation of differentiated specialty drug products to treat unmet 
medical needs, including conditions which qualify for Orphan drug status. 
 
 
The company has a portfolio of product candidates derived from its Known 
Molecular Entity (KME(TM)) approach to drug re-profiling and development and 
aims to bring its products to the market either directly or through 
out-licensing or other partnering arrangements. 
 
 
AGI's common shares are listed on the Alternative Investment Market of the 
London Stock Exchange (AIM) and on the Irish Enterprise Exchange of the Irish 
Stock Market (IEX) as AGI. 
 
 
 
 
For further information please see www.agitherapeutics.com. 
 
 
Statements contained within this press release may contain forward-looking 
comments which involve risks and uncertainties that may cause actual results to 
vary from those contained in the forward-looking statements. In some cases, you 
can identify such forward-looking statements by terminology such as 'may', 
'will', 'could', 'forecasts', 'expects', 'plans', 'anticipates', 'believes', 
'estimates', 'predicts', 'potential', or 'continue'. Predictions and 
forward-looking references in this press release are subject to the satisfactory 
progress of research which is, by nature, unpredictable. Forward projections 
reflect management's best estimates based on information available at the time 
of issue. 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 MSCEFLFLKBBFFBQ 
 

AGI (LSE:AGI)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024

AGI (LSE:AGI)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024